Trials / Unknown
UnknownNCT05528406
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 (BRAF V600E Inhibitor) in Advanced Solid Tumor With BRAF V600 Mutation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 (BRAF V600E Inhibitor) in Advanced Solid Tumor With BRAF V600 Mutation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX208 | 900mg bid po |
Timeline
- Start date
- 2022-10-20
- Primary completion
- 2024-10-30
- Completion
- 2025-06-01
- First posted
- 2022-09-06
- Last updated
- 2022-09-06
Source: ClinicalTrials.gov record NCT05528406. Inclusion in this directory is not an endorsement.